KC
CMLTU

Kepos Capital’s CM Life Sciences III Inc. Unit CMLTU Stock Holding History

Kepos Capital’s Portfolio CMLTU Stock Details CMLTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-475,400
Closed -$5.21M – 646
2021
Q2 		$5.21M Buy
+475,400
New +$5.13M 0.39% 121

Other funds holding CMLTU

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PTC
Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
AMH
Apollo Management Holdings New York $7.6B AUM 23.97% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Kepos Capital's CMLTU Position: Q3 2021 in Review

Kepos Capital sold out of CM Life Sciences III Inc. Unit (CMLTU) in Q3 2021, closing a stake of 475,400 shares — an estimated $5.21M sold.

Kepos Capital first reported a position in CMLTU in Q2 2021 and held it in 1 quarter. The position peaked at $5.21M in Q2 2021. 28 funds tracked by Wall St. Rank hold CMLTU as of Q3 2021.

  • Kepos Capital reported no remaining CM Life Sciences III Inc. Unit position as of Q3 2021 after selling out during the quarter.
  • Kepos Capital sold 475,400 CM Life Sciences III Inc. Unit shares in Q3 2021, an estimated $5.21M.
  • Kepos Capital first reported a position in CM Life Sciences III Inc. Unit in Q2 2021 and held it in 1 quarter.
  • Kepos Capital's CM Life Sciences III Inc. Unit position peaked at $5.21M in Q2 2021.
  • 28 funds tracked by Wall St. Rank held CM Life Sciences III Inc. Unit as of Q3 2021.

Based on Kepos Capital's 13F filing for Q3 2021, filed 12 Nov 2021.